1. Web alert

   News Pages: 55 - 56

2. The addition of angiotensin receptor blockers to angiotens-inconverting enzyme inhibitors—What has time told us?

   • Mary Rose Fabi
   • John R. Teerlink

   OriginalPaper Pages: 59 - 64

3. The risks and benefits of aldosterone antagonists

   • Domenic A. Sica

   OriginalPaper Pages: 65 - 71

4. The impact of race on response to RAAS inhibition

   • Thomas W. Wallace
   • Mark H. Drazner

   OriginalPaper Pages: 72 - 77

5. Imaging the renin-angiotensin-aldosterone system in the heart

   • Jamshid Shirani
   • Maria L. Loredo
   • Vasken Dilsizian

   OriginalPaper Pages: 78 - 86

6. Combination pharmacologic therapies for heart failure: What next after angiotensin-converting enzyme inhibitors and beta-blockers?

   • Osama A. Ibrahim
   • Mark E. Dunlap

   OriginalPaper Pages: 89 - 93

7. When to initiate beta-blockers in heart failure: Is it ever too early?

   • Gregg C. Fonarow

   OriginalPaper Pages: 94 - 99

8. Beta-blockers in selected heart failure populations

   • Jalal K. Ghali

   OriginalPaper Pages: 100 - 105